1. Home
  2. MDWD vs LANV Comparison

MDWD vs LANV Comparison

Compare MDWD & LANV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MDWD
  • LANV
  • Stock Information
  • Founded
  • MDWD 2000
  • LANV 2015
  • Country
  • MDWD Israel
  • LANV China
  • Employees
  • MDWD N/A
  • LANV N/A
  • Industry
  • MDWD Medicinal Chemicals and Botanical Products
  • LANV Blank Checks
  • Sector
  • MDWD Health Care
  • LANV Finance
  • Exchange
  • MDWD Nasdaq
  • LANV Nasdaq
  • Market Cap
  • MDWD 230.6M
  • LANV 258.1M
  • IPO Year
  • MDWD 2014
  • LANV N/A
  • Fundamental
  • Price
  • MDWD $19.33
  • LANV $2.20
  • Analyst Decision
  • MDWD Strong Buy
  • LANV
  • Analyst Count
  • MDWD 2
  • LANV 0
  • Target Price
  • MDWD $35.00
  • LANV N/A
  • AVG Volume (30 Days)
  • MDWD 52.0K
  • LANV 39.1K
  • Earning Date
  • MDWD 08-13-2025
  • LANV 08-25-2025
  • Dividend Yield
  • MDWD N/A
  • LANV N/A
  • EPS Growth
  • MDWD N/A
  • LANV N/A
  • EPS
  • MDWD N/A
  • LANV N/A
  • Revenue
  • MDWD $19,213,000.00
  • LANV $340,211,202.00
  • Revenue This Year
  • MDWD $20.80
  • LANV $11.74
  • Revenue Next Year
  • MDWD $26.92
  • LANV $11.11
  • P/E Ratio
  • MDWD N/A
  • LANV N/A
  • Revenue Growth
  • MDWD N/A
  • LANV N/A
  • 52 Week Low
  • MDWD $14.14
  • LANV $0.91
  • 52 Week High
  • MDWD $24.00
  • LANV $2.69
  • Technical
  • Relative Strength Index (RSI)
  • MDWD 43.03
  • LANV 53.77
  • Support Level
  • MDWD $19.11
  • LANV $2.00
  • Resistance Level
  • MDWD $19.87
  • LANV $2.51
  • Average True Range (ATR)
  • MDWD 0.57
  • LANV 0.14
  • MACD
  • MDWD -0.21
  • LANV 0.01
  • Stochastic Oscillator
  • MDWD 27.77
  • LANV 39.22

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

About LANV Lanvin Group Holdings Limited

Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.

Share on Social Networks: